1616807-77-2

Basic information

• Product Name: N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide
• Synonyms: N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide
• CAS NO: 1616807-77-2
• Molecular Weight: 398.406
• Mol File: 1616807-77-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide(1616807-77-2)
• EPA Substance Registry System: N-(3,4-difluorophenyl)-5-(N-(1-ethylcyclopropyl)sulfamoyl)-2-fluorobenzamide(1616807-77-2)

Safety Data

• Hazardous Substances Data: 1616807-77-2(Hazardous Substances Data)

Upstream product

• 174886-06-7 1-ethylcyclopropylamine hydrochloride 
• 1616809-39-2 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride 
• 949485-81-8 5-(chlorosulfonyl)-2-fluorobenzoyl chloride 
• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 

Relevant articles and documents

NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION

The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. (Formula (I)) Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.